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SUMMARY 
Atopic dermatitis (AD) is a complex, often lifelong allergic disease affecting around 10 % of both 
dogs and humans. The hallmark symptom is severe pruritus, causing a lowered quality of life. Mast 
cells (MCs) are known to play an important part of the immunopathogenesis, promoting a faulty T 
helper cell type 2 (Th-2) response which follows by a production of specific immunoglobulin E 
(IgE) antibodies towards environmental allergens (Ag). To further investigate the role of MCs and 
its mediators in the progression of AD, a low-calcemic vitamin D3 analog (MC903) was used to 
induce AD-like symptoms locally on the ears of two different knock-out (KO) mouse strains. The 
first strain was W
sh-/-
 mice deficient in MCs. The second strain was mice deficient in mouse mast 
cell protease 4 (mMCP-4
-/-
), a homolog to the human and canine MC chymase (MCC).  
The hypothesis was to observe an increase in inflammatory parameters following MC903-treatment, 
such as migration of inflammatory cells, higher amount of inflammatory mediators and clinically 
observed ear thickening. Thereby, MC903 would be proven to induce a functioning AD animal 
model. The results showed that daily topical MC903 application on the left ear induced changes 
mimicking AD macroscopically, microscopically and biochemically, including a Th-2 response 
represented by associated cytokines. No changes were seen in the vehicle-treated ears (treated with 
ethanol) used as an internal control.  
The epithelial cell-derived thymic stromal lymphopoietin (TSLP) appeared to be an important 
cytokine in promoting the skin inflammation since the amount of TSLP was markedly high locally 
in the MC903-treated ears. In MC-deficient mice, TSLP-levels were significantly lower, thus 
implicating a central role of MCs in this model. Although the presence of MCs caused higher levels 
of both TSLP and interleukin 33 (IL-33) after MC903-treatment, the clinical appearance in W
sh+/-
 
mice was milder compared to mice lacking MCs. This indicates that MCs do promote the AD-like 
skin inflammation caused by MC903, but at the same time prohibit the inflammation from being too 
excessive.  
The results from a small in vitro study performed as a part of this study, proved that MC903 also 
activates MCs directly to degranulate. The MCC homolog mMCP-4 did on the contrary only 
contribute to the lowering of IL-33 levels, most likely through cleavage of the cytokine by mMCP-
4, therefore no apparent role of MCC could be observed. In the cleavage study of TSLP, a more 
rapid cleavage of TSLP was mediated by tryptase than chymase. Thus, as a continuation of this 
study, the investigation of the role of tryptase in the MC903-induced AD-model would be of high 
interest.   
In conclusion, MC903 application induced an AD-like local inflammation, thus showing that the 
method provides a functioning AD-model. MCs contribute to disease progression through cytokine 
production, but have at the same time a limiting role in the course of inflammation.  
  
SAMMANFATTNING 
Atopisk dermatit (AD) är en komplex och ofta livslång allergisk sjukdom som drabbar ca 10 % av 
alla människor och hundar. Svår klåda kännetecknar sjukdomen, vilket medför en försämrad 
livskvalitet för drabbade individer. Det är känt att mastceller (MC) är viktiga i immunopatogenesen, 
då de bidrar till att skapa ett onormalt immunsvar med typ 2 T-hjälparceller (Th-2). Dessa är 
förknippade med produktionen av immunoglobulin E (IgE) antikroppar mot allergen i omgivningen.  
I detta försök användes en vitamin D3-analog (MC903) för att inducera AD-liknande symtom lokalt 
på öronen, tillhörande två olika knock-out (KO) musstammar. Detta gjordes för att ytterligare 
undersöka hur MC och dess mediatorer kan bidra i sjukdomsutvecklingen av AD. Den ena KO 
musstammen (W
sh-/-
)
 
saknar MC och den andra KO musstammen saknar mastcellsproteas 4 
(mMCP-4
-/-
), en mushomolog till mastcellsproteaset kymas (MCC) hos människa och hund.   
Hypotesen i försöket var att lokalbehandling med MC903 skulle öka de inflammationsparametrar 
som valts att studera i studien (klinisk sjukdomsutveckling, migration av inflammatoriska celler, 
mängd av inflammatoriska mediatorer), vilket skulle bevisa att MC903 skapar en funktionell AD-
modell. Resultatet i studien visade att en upprepad applikation av MC903 på ena örat inducerade 
förändringar som liknar dem som ses vid naturligt förekommande AD, både makroskopiskt och 
mikroskopiskt samt biokemiskt. Inga förändringar sågs i det andra örat som behandlades med 
vehikel (etanol) och användes som en intern kontroll.  
TSLP (thymic stromal lymphopoietin), ett cytokin som främst produceras av epitelceller, bedömdes 
i försöket ha en viktig funktion i utvecklingen av den AD-liknande hudinflammationen då de 
MC903-behandlade öronen innehöll mycket stora mängder TSLP. Hos mössen som saknade MC 
var TSLP-nivåerna signifikant lägre, vilket tyder på en central roll för MC i denna modell. Även om 
MC903-behandlingen inducerade högre cytokinnivåer (bl.a. TSLP, interleukin 33 (IL-33)), var den 
kliniska bilden mildare hos W
sh+/- 
möss jämfört med W
sh-/- 
möss (som saknar MC). Detta indikerar 
en drivande roll för MC i den AD-liknande hudinflammationen som uppstår efter applikation av 
MC903, samtidigt som MC har en begränsande roll för inflammationen. En liten in vitro studie som 
utfördes under detta projekt, bevisade att MC903 även kan aktivera MC direkt till degranulering.  
Ingen tydlig roll för mMCP-4 i denna musmodell kunde påvisas, då det enbart minskade nivåerna 
av IL-33, troligen via klyvning av cytokinet. Klyvningsstudien av TSLP visade en snabbare 
nedbrytning av TSLP med tryptas än med kymas. Som en fortsättning på denna studie vore det 
därför intressant att närmre undersöka rollen av tryptas i den MC903-inducerade AD-modellen. 
Sammanfattningsvis gav en upprepad applikation av MC903 uppkomst till en AD-liknande, lokal 
hudinflammation vilket visar att metoden fungerar som en AD-modell. MC bidrar i 
sjukdomsutvecklingen genom att höja cytokin-nivåerna, men förhindrar samtidigt en överdriven 
inflammation. 
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INTRODUCTION 
Atopic dermatitis is a lifelong disease with high prevalence (approximately 10 %) in both children 
and dogs, caused by an inflammatory response against common environmental Ag (Marsella & 
Girolomoni, 2009).  Pruritus is the hallmark symptom of human as well as canine AD, which causes 
a lowered life quality of affected humans and dogs, as well as dog owners (Linek & Favrot, 2010). 
The pruritus is followed by typical lesions such as erythematous macules and flaky skin. These 
early lesions, with similar distribution in humans and dogs (Marsella & Girolomoni, 2009), 
aggravates into chronic lesions with hyperpigmentation and lichenification due to self-trauma. The 
MC has for a long period of time been considered an important part of driving the immune system 
towards a faulty Th type 2 reaction against Ag, but exactly in what way is still unknown. Although 
extensive scientific research has been done to examine the immunologic background of AD, there 
are without doubt discoveries left to be unveiled.  
The purpose of this project was to establish a mouse model mimicking AD, induced by a low-
calcemic vitamin D3-analog MC903 (as described by Li et al. in 2006). MCs from humans, dogs 
and mice share many morphological and functional characteristics despite different origin, why the 
use of mouse models to widen the understanding of MC-dependent immunologic disorders (such as 
AD) is highly relevant. Therefore, a KO strain of mice lacking MCs (W
sh
) was used to investigate 
the role of MCs in this mouse model mimicking both human and canine AD (Grimbaldeston et al., 
2005). The predominantly expressed type of MCC in mice is mMCP-4 (Pejler et al., 2007) which 
share expression pattern with the human and canine MCC, as well as close to identical cleavage 
specificity and similar tissue distribution as the human MCC (Hellman & Thorpe, 2013). To further 
investigate the role of MCC, a KO mice lacking mMCP-4 was also used in this study.  
The questions aimed to be answered were if MC903-induced AD is MC-dependent and how the 
inflammation differs when the tissue is free from MCs or mMCP-4 in KO mice strains, compared to 
when present in the tissue. The hypothesis, based on previously performed studies, was that 
MC903-treatment would increase the inflammatory parameters analyzed (e.g. clinical scoring, 
migration of inflammatory cells, inflammatory mediators), thus confirming that the model is 
mimicking AD. Significant differences between the KO and WT mice were expected since MCs are 
known to contribute in the immunopathogenesis of AD, thereby proving the importance of MCs in 
modulating the inflammation. 
2 
 
LITERATURE REVIEW 
Mast cells 
Characteristics 
MCs have a characteristic morphologic appearance, whether of human, canine or murine origin. 
Their prominent feature is a large amount of cytoplasmic granules (secretory lysosomes), which are 
pronouncedly colored by toluidine blue (TB) (Garcia et al., 1998). The nucleus, which could be 
covered by granules, is round, especially after degranulation. Canine MCs varies between 7.5 and 
12 μm in diameter (Garcia et al., 1998), whereas human MCs varies between 5 –10 μm 
(Voehringer, 2013). MCs originate from hematopoetic stem cells in the bone marrow and emigrate 
as precursor cells into the peripheral tissues were they mature and terminally differentiate. Their life 
span varies from weeks to months, according to Voehringer in a recent review article (2013). 
Localization 
MCs are present in most tissues but more prominent in tissues in contact with the surrounding 
environment, i.e. the skin, intestine and mucous membranes (Tsai et al., 2011; Voehringer, 2013). 
Moreover, they tend to assemble close to nerves, lymphatic vessels and blood vessels. This strategic 
placement gives MCs the capability to influence other inflammatory cells and to attract them into 
tissue migration via a large range of inflammatory mediators whenever necessary. Thus, MCs are 
able to act directly against environmental allergens and have a key role in driving the immune 
response toward a faulty reaction against non-harmful Ag, such as house dust mites or pollen, 
which causes the allergic reaction that AD is a symptom of. This refers to both human and canine 
MCs (Liu et al., 2011; DeMora et al., 2006).  
Mediators 
MCs carries preformed mediators in secretory granules which can be released upon several stimuli 
and used to create an instant immune reaction, for example when allergens cross-link two IgE 
antibodies connected to the high affinity receptors, FcεRI, on the surface of a MC (Voehringer, 
2013). These granula mainly contain histamine, proteases (e.g. MCC, tryptase), cytokines (e.g. ILs, 
tumor necrosis factors (TNFs)) and proteoglycans (heparin) (Metcalfe et al., 1997). MCs do also 
have the capacity to produce new mediators from lipids in their cell membrane via arachidonic acid, 
such as prostaglandins and thromboxanes via cyclooxygenase and leukotrienes via lipoxygenase. 
Last but not least, MCs can up-regulate their cytokine expression after a longer time of antigen-
binding or other stimuli. Cytokines produced by MCs are mostly pro-inflammatory, for example IL-
4 that stimulates B-cells into producing IgE and TNF that has a positive effect on the migration and 
activation of other immunological cells (Tsai et al., 2011). However, MCs are also able to limit the 
inflammation through IL-10, for example by decimating the production of pro-inflammatory 
mediators from T-cells and keratinocytes.  
Activation 
Although the most known pathway of MC activation is through antigen cross-linking of two IgE 
bound to FcεRI high affinity receptor, there are many more ways to activate these immune cells. In 
fact, MCs have a very important function as sentinel cells in the innate immune response and not 
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just in initiating the acquired immune response (Metz et al., 2008). The placement of MCs in 
epithelial tissues enables notable contribution to the defense against pathogens, together with the 
expression of pattern recognition receptors (PRRs) on MC surface, creating an early response 
against both extra- and intracellular pathogens and their products. Activation of MCs through these 
PRRs induces the release of cytokines and antimicrobial peptides from not only MCs, but from 
other immune cells such as dendritic cells (DCs) as well (St. John & Abraham, 2013). MCs do also 
recognize and become activated by mediators that are upregulated during bacterial infections, such 
as complement factors (Metz et al., 2008). Furthermore, the MCs innate immune response against 
pathogens includes a direct defense towards bacterial endotoxins, which seem to be degraded by 
MC proteases. 
Associations with atopic dermatitis 
Through their strategic placement in the skin and wide range of inflammatory mediators excreted, 
MCs are able to make substantial effects on the local environment, through regulation of vascular 
permeability, recruitment of other inflammatory cells, alteration of the functioning of inflammatory 
cells as well as epithelial cells, professional antigen presentation and induction of a cytokine-driven 
Th-2 polarization (Liu et al., 2011). Comparative in vitro studies by DeMora et al. (1996) have 
shown that MCs derived from atopic dogs are more active than MCs from normal dogs. These 
changes include significantly higher amounts of histamine in the skin MCs, as well as higher 
spontaneous secretion of histamine from MCs isolated from atopic dogs. 
Atopic dermatitis 
Background 
Atopic dermatitis is a skin inflammation characterized as a hypersensitivity reaction type 1, which 
implies an exaggerated Th-2 response and subsequent production of IgE antibodies against non-
harmful Ag in the surrounding environment (Galli et al., 2008). According to Halliwell in 2006, the 
definition of canine AD is: 
“A genetically-predisposed and pruritic allergic skin disease with characteristic clinical features. It 
is associated most commonly with IgE antibodies to environmental allergens”.  
As described above, heritable factors contribute to the development of AD. This is also true for 
human AD, were a large birth cohort study by Dold et al. (1992) showed a higher risk for a child to 
develop symptoms of AD with both parents suffering from the same disease (odds ratio (OR) 3.4), 
compared to the development of asthma (OR 1.5) or allergic rhinitis (OR 1.4) if both parents share 
those diseases. 
One of the currently known inheritable trait of atopic individuals is alterations in the protective skin 
barrier; atopic dogs have consistently more unorganized components such as intercellular lipids and 
corneocytes in the stratum corneum and granulosum, before Ag challenge and in non-lesional skin, 
compared to non-atopic individuals (Marsella et al., 2010). These changes are visible with electron 
microscopy and the impaired skin barrier is likely to facilitate the contact between Ag and 
immunologically active cells. In humans, a null mutation in the gene coding for filaggrin, a protein 
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with important function in the skin barrier through the differentiation of epidermal cells, is 
associated with a significantly higher risk for AD-development (Palmer et al., 2006). In dogs, a 
genome-wide analysis showed a strong association between AD and two single nucleotide 
polymorphisms (SNP) in the gene coding for Plakophilin 2 which affects the function of 
desmosomes as adhesion proteins, hence important in the skin barrier (Tengvall et al., 2013). For 
the complete development of atopy, the immune cells have to display certain changes in function as 
well. In skin specimens from canine AD-patients, MCs are proven to be more reactive after 
activation by antigen cross-linking of IgE to FcεRI, in terms of histamine release (DeMora et al., 
1996).  
Beyond these congenital predisposing abnormalities, there are also environmental factors that 
contribute to the evolvement of AD. In fact, heritage and environmental factors have in a breeding 
group of guiding dogs for the blind been shown to be of almost equal importance (Shaw et al., 
2004). One environmental risk factor is early exposure to Ag, in this case house dust mites, 
Dermatophagoides farinae, especially in combination with an inherited predisposition for high IgE-
production (Schiessl et al., 2003). Another risk factor, shown in a study with 1500 pruritic dogs, is 
indoor living condition (Favrot, 2010) which also enables contact with the house dust mite Ag 
which is the most common cause of AD in Swedish dogs (Öhlén, 1992).  
Ultimately, for the AD to establish in a patient, scratching with following self-damage on the skin is 
required. The cause of pruritus has for a long period of time been investigated, and there are most 
likely multiple factors involved, including TSLP, IL-25, IL-33 (Wilson et al., 2013), IL-2 and IL-31 
(Kabashima, 2013). Pruritus and its mediators are further reviewed in later paragraphs. 
Clinical appearance 
AD, in humans also known as eczema, is a complex disease that in most part shares the same 
features in both human and canine patients (see Table 1, adapted from Marsella & Girolomoni, 
2009). In both species, pruritus is the primarily and most prominent component, which leads to 
worsening of the inflammation through itching and self-damage (Marsella & Girolomoni, 2009). 
After pruritus, lesions with erythem and flaky skin appear which in dogs quickly aggravates into 
alopecia, lichenification and hyperpigmentation of the skin, if the itching continues (Olivry et al., 
2010). Affected areas are also similar between the species: humans have most of their lesions in 
flexural surfaces of the joints (for example inner sides of knees and elbows) and hands, and dogs are 
pruritic in surfaces in contact with the floor (for example axillar and inguinal regions, paws and 
ears) (Marsella & Girolomoni, 2009). Furthermore, the first clinical signs of AD occur early in life 
of both humans and dogs. However, canine AD is considered to be a lifelong disease in all cases 
(Marsella & Girolomoni, 2009), whereas human patients might outgrow their symptoms with 
increasing age. In a Swedish study from 2000, Gustafsson et al. observed that around 35 % of the 
children suffering from eczema at the starting point (4 – 35 months old) did not show any skin 
changes at the end of the study (5 – 7 years old).  
Another difference between the clinical appearance in human and canine patients is that for 
humans, it is common to go through the so called atopic march, i.e. a development of the disease 
into allergic rhinitis/conjunctivitis and asthma (Spergel, 2010). Only a few percent of the atopic 
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dogs develop rhinitis or conjunctivitis and no dogs have been reported to develop asthma (see Table 
1, adapted from Marsella & Girolomoni, 2009). Gustafsson et al. (2000) showed that 50 % of the 94 
participating children diagnosed with eczema at 4-35 months of age developed allergic rhinitis and 
47 % developed asthma before 7 years of age.   
Table 1. Similarities between human and canine atopic dermatitis 
 
 
 
 
 
 
 
 
 
 
Adapted with permission from Marsella & Girolomoni, 2009  
Microscopically visible features of atopic dermatitis 
Lesional skin from humans suffering with AD shows so called spongiotic changes when analyzed 
by histopathology and electron microscopy (Kamsteeg et al, 2010). This means an edema in the 
epidermis that widens the intercellular space, thus impairing the skin barrier. An experimental study 
by Kamsteeg et al. (2010) showed that atopic dogs had similar changes as humans, including a 
disorganized stratum corneum with lower density than in normal dogs. Ag challenge in normal dogs 
led to a mildly increased intercellular space whilst in atopic dogs, severe spongiotic changes were 
seen. Together with the spongiosis, hyperplasia of the epidermis was seen as a typical histological 
finding in lesional skin of dogs with AD, corresponding to the thickening of the skin seen 
macroscopically (Olivry et al., 1997). In skin biopsies from ten human AD patients, epidermis was 
significantly increased (>50 %) in lesional skin compared to non-lesional skin, a change that was 
even more apparent in chronic AD compared to acute lesions (Gittler et al., 2012). 
Moreover, it is typical to see a dermal infiltration of inflammatory lymphocytes and MCs that 
secrete cytokines associated with a Th-2 type cytokine profile (e.g. IL-4, IL-13). Interestingly, an in 
vitro study from 2011 by Kamsteeg et al. showed that skin equivalents grown from human 
keratinocytes develop typical spongiotic AD-lesions when cultured with IL-4 and IL-13. In the 
same study, these cytokines were also shown to increase fragmentation of deoxyribonucleic acid 
 
Human AD Canine AD 
Prevalence (%) 5 – 20 of children 10 – 15 in total 
Genetical inheritage Yes Yes 
Age of onset (years) <1 – 5 1 – 3 
Pruritus Severe Severe 
Skin areas affected Face, skin folds Face, skin folds 
Spongiotic dermatitis Yes Yes 
High skin colonization of Staphylococcus spp. Yes Yes 
Th-2 domination of immune response Yes Yes 
IgE-specific response (%) 55 – 90 80 
Atopic march Yes No 
Rhinitis and conjunctivitis (%) <5 35 
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(DNA) which according to the authors implies that the higher frequency of keratinocyte apoptosis 
seen in acute AD-lesions could be induced by Th-2 cytokines such as IL-4 and IL-13.  
Prevalence 
Because of the complexity of AD and its appearance, prevalence studies have to be considered 
merely qualified estimations. These give percentage numbers from 3 to 15 of the total canine 
population (Hillier & Griffin, 2001). In Sweden, the prevalence according to calculations using 
national insurance companies’ data bases was 3 % between year 1995 and 2002 (Holm, 2007). In 
humans, a lifetime prevalence study in USA showed that up to 17 % of school children suffered 
from AD (Laughter et al., 2000) and the disease is also a major problem in developing countries 
according to a global prevalence study by Odhiambo et al. (2009). 
Immunopathogenesis including the role of mast cells 
Basic immunology 
As previously mentioned, atopy is categorized as a type 1 hypersensitivity reaction associated with 
IgE antibodies directed towards Ag (Galli et al., 2008), which implies the involvement of Ag-
presenting cells (APC), e.g. DCs. These migrate to the regional lymph nodes where they present 
antigen to naïve T-lymphocytes, leading to the formation of T-h cells. MCs are also able to present 
antigens and thereafter drive the immune response toward a Th-2 cell type associated with humoral 
immunity and IgE production, through secretion of IL-4 (Metcalfe et al., 1997). IL-4 is a cytokine 
which presence has been shown to be required for a Th-2 response in vitro (Voehringer, 2013) and 
is expressed by more cells in both lesional and non-lesional skin of human AD patients compared to 
normal controls (Hamid et al., 1994). In a study by Nuttall et al. from 2002, skin biopsies from 
atopic dogs were shown to express significantly higher levels of IL-4 mRNA compared to healthy 
controls. Schlotter et al. did a similar study in 2011, showing a higher expression of the Th-2 
cytokine IL-13 in the skin of atopic dogs compared to the controls, as well as a lowered expression 
of the Th1-associated cytokine IL-12. Another important cytokine is the epithelial cell-derived 
cytokine TSLP which has in an in vitro study been shown to activate and support survival of the 
professional APC, DC (Soumelis et al., 2002). This leads to the production of Th-2 associated 
cytokines such as IL-4 and IL-13 from naïve T-cells. The Th-2 cells stimulate B-cells to proliferate 
and produce antibodies (IgG, IgE) towards the Ag, which lead to sensitization of MCs by Ag-
specific IgE binding to the high affinity receptor FcεRI. MC activation occurs through cross-
binding of Ag with two IgE bound to FcεRI, which subsequently leads to the release of mediators 
which causes the allergic skin inflammation (Voeringer, 2013).  
This IgE-associated immune response is an important part of the immunopathogenesis, however, 
explaining only one part of the complex background of AD. In fact, there are many AD-patients 
who do not carry any traceable amounts of Ag-specific IgE. According to Marsella & Girolomoni 
(2009), this refers to 20 % of atopic dogs and 10 – 45 % of atopic humans. Consequently, the 
immunological background of AD involves not only the adaptive, but also the innate immune 
system. For example, epithelial cell-derived cytokines like TSLP could directly activate innate 
immune cells such as MCs without the involvement of B- or T-cells, according to Wu et al., 2010. 
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TSLP and the related cytokine IL-33 do also have an important part in promoting the Th-2 
associated cytokine cascade seen in AD-skin (Park et al., 2013; Iikura et al., 2007). 
Early phase of atopic dermatitis 
Experimental studies in atopic dogs showed a biphasic pattern with an early and a late reaction 
phase, and that MCs play an important role in both phases (Olivry et al., 2001). First of all, the Ag 
has to come in contact with immunologically active cells, which in both humans and dogs occurs 
via inhalation or by the epicutaneous route, the later though being the most important route in dogs 
(Marsella et al., 2006). The fact that AD in dogs is not as often associated with respiratory 
symptoms as in humans could be an explanation to why Ag in contact with the skin give the most 
potent inflammation in dogs, compared to air-born Ag (Marsella et al., 2006). Sensitized MCs, with 
Ag-specific IgE bound to FcεRI, that come in contact with the same Ag once again, are 
immediately activated (Galli et al., 2008). This activation leads to MC degranulation with the 
release of a broad range of mediators that create an almost acute inflammation after Ag contact, 
thus creating the early phase of the allergic inflammation.  
Late phase of atopic dermatitis 
The acute inflammation caused by MC mediators lead to pruritus, which is the hallmark symptom 
of AD and is often present before any visible changes appear in the skin (Favrot et al., 2010). MCs 
contribute to pruritus through mediators that have the ability to provoke an itching sensation via 
nociceptive receptors on sensory neurons (Galli et al., 2008). The MC mediator histamine is a well-
known and important prurinogen, but the fact that anti-histamines only have a limited impact on the 
pruritus in both humans and dogs, supports the involvement of other mediators as well. Known 
pruritic mediators are for example nerve growth factor (NGF) which is produced by keratinocytes 
and supports further innervation of the skin, thus enabling the sensation of pruritus (Kabashima, 
2013). The blood level of NGF is also related to disease severity of AD. In turn, nerve cells produce 
Substance P that stimulates dermal fibroblasts to release artemin, which leads to a lowering of the 
threshold towards a temperature-induced itch seen in human AD patients. Interestingly, Substance P 
has also got the ability to activate MCs (Kawakami et al., 2009) and can be degraded by the MC 
protease chymase (Caughey et al., 1988), thus indicating a role of MCs in balancing the pruritus. 
Moreover, MCs are able to produce both Substance P and NGF, thus giving them opportunity to 
affect the nervous system. Other possible prurinogens described further by Kabashima in a newly 
published review article (2013) is endothelin and acetylcholin from endothelial cells, IL-2 and IL-
31 from T-cells and reactive oxygen from eosinophils. In a study from 2006, mRNA expression of 
IL-31 was significantly upregulated in skin specimens from humans with AD (Sonkoly et al., 
2006). This result was most apparent in patients with severe pruritus. In skin specimens from 
humans with the non-pruritic skin disease psoriasis, no significant upregulation of IL-31 could be 
observed. Moreover, non-lesional skin from AD-patients had four times higher mRNA-levels 
compared to skin from healthy humans. This could, according to the authors, imply that IL-31 is 
one of the factors that lead to pruritus before a skin inflammation is visible (Sonkoly et al., 2006). 
The late reaction phase continues with migration of other immunologically active cells to the 
affected skin, such as granulocytes (i.e. neutrophils and eosinophils) and lymphocytes. MC 
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mediators contribute to this event, through alterations in blood flow which enables vascular 
adhesion and migration of neutrophils (Metcalfe et al., 1997), as well by attracting other immune 
cells to the area, for example via IL-8 and TNF-α (Galli et al., 2008). A small study in dogs done by 
Olivry et al. (2001) showed a significantly higher rise in neutrophil counts in atopic dogs after 
experimental Ag skin injection (most apparent after 6-12 hours), compared to non-atopic dogs. T-
lymphocyte and DC numbers peaked later than the neutrophils, at 24 hours after Ag challenge. The 
same author showed in a previous study that the cell infiltration in the skin of atopic dogs consisted 
of low numbers of neutrophils, which indicates that these cells might not be as important in 
naturally occurring AD as in experimental AD (Olivry et al., 2001). The exact function of 
neutrophils in AD is yet to discover. Not to be forgotten, MCs might also have a role in limiting the 
inflammation through mediators like IL-10 (Galli et al., 2008). 
Chronic phase of atopic dermatitis 
After pruritus has established in the AD-patient, changes in the skin develop. First, small papules, 
erythema and flaky skin are seen, lesions quickly worsening without treatment into explicit changes 
caused by scratching. These include lichenification and hyperpigmentation, as well as alopecia in 
dogs. Chronic lesions develop due to the self-induced trauma that sustains the skin inflammation via 
continuous release of inflammatory mediators, which further aggravate the pruritus in a vicious 
circle (Olivry et al., 2010). Analysis of biopsy specimens from humans suffering from AD has 
shown significant differences in the cytokine expression pattern between acute and chronic lesions. 
Acute lesions show a Th-2 immune response, dominated by IL-4, though IL-5, IL-10, IL-13 and IL-
33 are also expressed (Hamid et al., 1994; Gittler et al., 2012). Low expression of Th-1 cytokines 
such as IFNᵧ is seen. In chronic lesions, a decrease in IL-4 expression, an increase in IL-5 
expression and an increase of the Th-1 cytokine IFNᵧ is seen (Hamid et al., 1994; Gittler et al., 
2012), thus indicating a less important role of MCs in chronic AD.   
The disease also worsens as microbes often attach and grow in the defective skin. In fact, secondary 
infections infest 66 % of all atopic dogs according to Favrot et al. (2010). The most common 
microbe causing infection in canines, Staphylococcus pseudintermedius, has been shown to adhere 
with corneocytes (terminally differentiated keratinocytes) in significantly higher extent in both 
lesional and non-lesional skin of atopic dogs compared to normal dogs (McEwan et al., 2006). This 
colonization predisposes atopic dogs to pyoderma, and may be caused by the faulty Th-2 
microenvironment seen in AD according to the authors. In humans suffering from AD, more than 
90 % have skin colonization with Staphylococcus aureus, shown by Breuer et al. in 2002. Of all 
adult AD patients, 94 % were positive for the bacteria in swab tests from their skin. In a similar 
study, over 87 % of the investigated atopic dogs were colonized by S. pseudintermedius, compared 
to 37 % of normal dogs (Fazakerley et al. in 2009).  
Associations between specific MC-derived mediators and atopic dermatitis 
The following MC-mediators were chosen for further investigation in the experimental model of 
this study, due to their previously proven association with AD.  
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Thymic stromal lymphopoietin 
TSLP plays a key role in the innate immunity; it is involved in creating a Th-2 associated cytokine 
expression and subsequently induce a Th-2 type of allergic inflammation, without the involvement 
of T- and B-cells according to Park et al. (2013). Instead, TSLP activates innate immune cells 
directly via the TSLP-receptor (TSLPR) on the cell surface of immune cells, including MCs 
(Allakhverdi et al., 2007) and DCs. The activated immune cells then start to produce cytokines 
associated with a type 2 Th immune response, for example IL-4, IL-5, IL-13 and TNF-α (Ziegler, 
2012), cytokines that also are associated with AD. Furthermore, an in vitro study showed that TSLP 
was produced by human MCs incubated with IL-4 (Okayama et al., 2009), thus indicating that MCs 
may contribute to an allergic inflammation through production of TSLP. In the same study, TSLP 
was shown to be degraded by MC proteases, which could be a way for MCs to limit the 
inflammation. The increase in IL-4 seen in other mouse models mimicking atopy, was not seen in 
mice lacking TSLP in keratinocytes (Leyva-Castillo et al, 2013), suggesting that TSLP-expression 
is necessary for the Th-2 dominated immune response seen in patient with atopy.   
Genetic studies have shown significant associations between SNP in the gene coding for the TSLPR 
and human AD (Gao et al., 2010) as well as in canine AD (Wood et al., 2010). In fact, the gene 
coding for TSLPR was the only gene with SNP in atopic dogs of all eight breeds examined in a 
meta-analysis study. High TSLP expression by epithelial cells derived from atopic humans was 
observed by Soumelis et al. in 2002. In atopic dogs, TSLP expression was significantly up-
regulated in both inflammatory lesional and non-lesional skin (Klukowska-Rötzler et al., 2013). 
Keratinocytes produce TSLP in response to microbes, inflammation or trauma such as scratching, 
by which TSLP could have a part in aggravating the continuous inflammatory response seen in AD-
patients according to Allakhverdi et al., 2007. A recent study by Wilson et al., (2013) showed that 
an injection of TSLP into the cheek of a mouse induced a pronounced itch, whilst a vehicle-
injection (control substance) did not. This was true not only in WT mice, but also in mice lacking 
B- and T-cells (severe combined immunodeficient (SCID) and Rag
-/- 
mice respectively) as well as 
in mice lacking MCs (W
sh
). Therefore, the authors suggested that TSLP may induce itch through a 
direct activation of sensory neurons, without the involvement of inflammatory cells or their 
cytokines.  
Functionally, human and murine TSLP show significant homology (Ziegler, 2012), implying TSLP 
being a useful parameter to assess in AD-mouse models. A recent study, using an AD mouse model 
where AD was induced by repeated applications with house dust mite extract and Staphylococcal 
enterotoxin B on the mouse skin, showed that MCs were required for a maximal skin inflammation 
and that TSLP contributes to the inflammation (Ando et al., 2013). This was concluded since KO 
mice lacking TSLPR (TSLPR
-/-
) had significantly lower clinical scores (e.g. ear thickness) after 
induction of AD compared to WT-mice. Another AD-study in mice by Yoo et al. (2005) showed 
that transgenic mice over-expressing TSLP in the skin, spontaneously developed most of the 
features that are seen in AD-skin, i.e. epidermal thickening, dermal infiltration of leukocytes, local 
Th-2 associated cytokine production and presence of Th-2 cells in draining lymph nodes. 
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Interleukin 33 
Similar to TSLP, IL-33 is produced by epithelial cells following inflammatory stimuli (Miller, 
2011). The knowledge of IL-33 as an important inflammatory cytokine is currently expanding. IL-
33 carries the ability to activate Th-2 associated inflammatory cells such as MCs (Iikura et al., 
2007). In vitro, bone marrow-derived MCs were shown to express IL-33 mRNA when incubated 
with IgE (Hsu et al., 2010). MCs derived from peritoneal lavage were stained positive for IL-33 
with immunohistochemistry (IHC). In the same study, IL-33 levels were significantly lower in the 
skin from MC-deficient mice (W/Wv) when compared to WT mice. Hueber et al. (2011) showed 
that intradermal IL-33 injections every other day for 16 days caused a skin inflammation with 
epidermal thickening as well as a local increase in MC and neutrofil numbers. In W
sh-/-
 mice, the 
inflammatory response was delayed, thus indicating a role for MCs in the early phase of the IL-33 
induced inflammation according to the authors.   
A polymorphism in the gene coding for the IL-33 receptor (ST2) was shown in 2005 to be 
associated with AD in humans (Shimizu et al.). To further investigate this connection, Imai et al. 
(2013) used transgenic mice overexpressing IL-33 in the skin. This resulted in a spontaneously 
developed dermatitis mimicking AD, including the hallmark symptom pruritus. Skin sections 
showed infiltration of both MCs and eosinophils, including degranulated MCs. This activation of 
MCs by IL-33 was also apparent in the blood, since mice overexpressing IL-33 contained higher 
amounts of histamine and IgE in serum compared to WT mice.  
Mast cell protease chymase 
MCC is a chymotrypsin-like serine protease that is secreted through MC granules following 
activation of MCs (Badertscher et al., 2005). The most well known substance to be processed by the 
enzyme is Angiotensin 1, but MCC has a wide range of other substrates such as fibrinogen, 
components of the extracellular matrix (ECM), lipoproteins and several inflammatory substances, 
including Substance P (see a list with potential substrates in Pejler et al., 2007), associated with the 
pruritus that characterize AD (Kabashima, 2013). Experimental studies by Terakawa et al. (2008) 
using a mouse AD model induced by the chemical substance DNFB, showed that an oral chymase 
inhibitor (SUN13834) lowered skin inflammation and scratching behavior, thus indicating a role of 
MCC both in pruritus and clinical changes. In a small study by Badertscher et al. (2005), MCC was 
quantified using IHC in punch biopsy specimens from 19 humans suffering from AD. The results 
showed a significantly higher number of MCs containing MCC in lesional skin, compared to 
normal skin in the same individual and skin specimens from humans with psoriasis (both lesional 
and non-lesional). Moreover, non-lesional skin from humans with AD showed significantly more 
MCC than psoriatic skin. The authors finally discuss the possible involvement of MCC in the 
impairment of the skin barrier seen in AD, due to the ability of MCC to degrade ECM components, 
but if this assumption is correct is yet to discover. In a Swedish study from 2013 by Waern et al., 
also using mMCP-4
-/-
 mice, MCC was shown to have a protective role in an induced airway 
inflammation model. Therefore, an effect by MCC in the present study was hypothesized.  
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MATERIAL AND METHODS 
Laboratory work was performed at the Department of Biomedical Sciences and Veterinary Public 
Health, Section of Immunology, located at the Biomedical Centre (BMC) in Uppsala, Sweden. 
Experimental animals 
Two different types of KO mouse strains on C57Bl/6 genetic background were used in this study. 
The W
sh-/-
 mouse strain with nearly a total loss of MCs (Grimbaldeston et al., 2005) and the mMCP-
4
-/-
 mouse strain that only lacks the MC protease chymase (Tchougounova et al., 2003). Mice were 
six to nine weeks old; both female and males were used. Both strains were fertile, appeared 
clinically healthy and had a normal life span. As controls, heterozygous and WT litter mates were 
used. All of the animals were kept in a controlled environment at BMC in individually ventilated 
cages, cared for by trained staff and fed with R3 Pellets (Lantmännen). The methods and use of 
described mouse strains in experimental AD was approved by the Ethical Committee for Use of 
Experimental Animals in Uppsala.  
The number of animals used in this study is shown in Table 2. In the first experiment, the role of 
MCs in MC903-induced AD was investigated by comparing MC-deficient (W
sh-/-
) mice with 
heterozygote MC-competent mice (W
sh+/-
). As controls, five W
sh+/- 
and five W
sh-/- 
were used. In 
experiment 2 and 3, MC903-induced AD in mMCP-4-deficient, heterozygote and WT animals were 
scored in a blinded fashion, i.e. the genotype of the 36 treated mice and five control mice was 
determined by polymerase chain reaction (PCR) after the terminal endpoint of the experiment.  
Table 2. Number of animals used in the experiments 
  Genotypes Experiment 1 Genotypes Experiment 2 and 3 
 W
sh+/-
 W
sh-/-
 WT mMCP-4
+/-
 mMCP-4
-/-
 
Treated 7 7 6 19 11 
Controls 5 5 5 - - 
Induction of atopic dermatitis on ears by MC903 
An AD-like disease was induced by topical application of a low-calcemic vitamin D3-analog, 
MC903. This chemical substance is also known as calcipotriol (Dovonex), used for treatment of 
psoriasis. Several studies have been performed to investigate the functions of MC903 and its 
potential in AD-treatment. Li et al. (2006) showed that skin application of MC903 up-regulates the 
expression of TSLP in keratinocytes, which is also seen in the skin of human and canine AD-
patients (Soumelis et al., 2002; Klukowska-Rötzler et al., 2013).  This together with the fact that the 
known side effects of calcipotriol-treatment (redness, dry skin, pruritus) mimics AD-symptoms, 
rose a hypothesis that long-term skin-treatment with MC903 could induce an AD-like phenotype. Li 
et al. (2006) proved that this was true in WT mice as well as in KO mice deficient in B- and T-cells 
(RAG
-/-
), thus showing that the MC903-induced AD-phenotype was not dependent of either B- or 
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T-cells. Instead, the cellular infiltration in the MC903-treated skin consisted of eosinophils, DCs 
and MCs. Another study using MC903 to trigger AD-like symptoms showed that MC903-treatment 
induced T-cells to produce Th-2 associated cytokines (Elentner et al., 2009). Since cultured 
keratinocytes did not produce any other of the measured cytokines (e.g. IL-1, IL-2 and IL-4), the 
authors suggested that TSLP is the most important cytokine in mediating the function of MC903. In 
the same study, DCs were shown to be necessary for the development of an AD-like phenotype.  
In the present study, 1 nmol MC903 in 20 μl 95 % ethanol were topically applied on the left ear, 10 
μl on each side of the ear. On the right ear, the same amount of 95 % ethanol only was applied as an 
internal vehicle control. This procedure followed once a day for a total of 13 subsequent days. The 
development of AD-like changes was followed by photography, measuring of ear thickness using a 
digital engineer´s micrometer (Mitutoyo Corporation, Japan) and by clinical scoring: 0 = no 
symptoms, 1 = mild redness/swelling, 2 = redness/swelling, 3 = redness/swelling/bleeding.  
Sampling of material from mice 
Blood was obtained from the tail vein twice during the trial, at day 2 and day 6, in amounts up to 
100 μl. To enhance peripheral blood flow, a heating lamp was placed above the cage for five 
minutes before blood sampling. At the end of trial, mice were sacrificed using carbon dioxide 
(CO2). Thereafter, both ears, the spleen, the auricular lymph nodes, blood, and a piece of the tail 
were collected from all mice included in the three experiments plus 15 non-treated, age-matched 
controls with the same genetic background. In Figure 1, the anatomical location of the ear draining 
lymph nodes is shown (adapted from ICCVAM Immunotoxicology Working Group, 2001). All of 
the collected materials were used for different analyses in this study except for the spleens, which 
were frozen in -20˚ C and saved for future studies. The goal was to use materials from every 
individual KO mice in all analyses performed when possible, material from WT, heterozygous and 
control mice were selected either randomly or due to the amount of material available. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Anatomical location of the auricular lymph nodes (adapted with permission from ICCVAM, 2001). 
13 
 
Genotyping of WT, mMCP-4+/- and mMCP-4-/- mice 
Although being on the C57Bl/6 genetic background (with black coat color), the genotype in the W
sh
 
mouse strain is apparent in the phenotype since homozygous mice are white, heterozygous mice are 
black and white (with a white sash around the waistline) and WT mice are black, this phenomenon 
is caused by the inversion mutation in the c-kit gene that do not only inhibit MCs but also affects 
melanocytes (Grimbaldeston et al., 2005). Therefore, only black WT, mMCP-4
+/-
 and mMCP-4
-/-
 
C57Bl/6 mice were genotyped. 
Genotyping was performed using a KAPA Mouse Genotyping kit (KAPA Biosystems). A 2 mm
3
 
mouse tail fragment, combined with 10 µl extract buffer and 2 µl extract enzyme (kit appurtenant) 
in a small tube filled up with PCR-water to a final volume of 100 µl, were incubated for 10 minutes 
at 75˚C. Thereafter, the enzymes were inactivated during 5 minutes of incubation at 95˚C. After a 
quick vortexing of the tube, one minute centrifugation at 13’ revolutions per minute (RPM) created 
the DNA-containing supernatant used for amplification. Reaction component, other than 1 µl 
supernatant, was 10 µl master mix (5 µl forward, reverse and neoprimers respectively, 6 µl MgCl 
and 29 µl PCR water). Cycling steps followed as instructed in kit, with denaturation, annealing, and 
extension in different temperatures and time points, to amplify DNA. Samples were thereafter 
loaded to a 1 % agarose gel and run for 30-60 minutes at 200 V to separate PCR products. Results 
were read as follows: upper band (700 base pairs) corresponds to WT genotype; lower band (550 
base pairs) to KO genotype and both bands mean a heterozygous mouse.  
Histopathology of ears 
To estimate microscopically visible inflammatory parameters, histopathologic evaluation was 
performed on all mouse ears collected at the end of the trial. Cryostatic sectioning was done to 
make the procedure as efficient as possible because of the project’s time limitation. Ears were cut 
into two halves; one half of the ears were soaked in 1 ml of 30 % sucrose for 48 h before they were 
embedded in medium (CryoMount), and quick frozen on dry ice. Subsequently, the embedded 
tissues were sectioned in a Cryostat at 8 μm slices and transferred onto microscope slides 
(Superfrost
®
 plus, Thermo Scientific). The sectioned tissues were stained with hematoxylin-eosin 
(H&E) or TB to study cellular infiltration. Slides were digitally captured for presentation using 
NIS-Elements Microscope Imaging Software (Nikon) in a Nikon Eclipse 90i microscope.   
Inflammatory cell counts 
Lymph node cell counts 
Each auricular lymph node (draining the ears) was mixed with 600 μl phosphate buffered saline 
(PBS) into a suspension. Lymph nodes from all of the treated mice in the trial plus one lymph node 
from each of the 15 control animals was analyzed. In the first experiment on W
sh
 animals, 100 μl 
lymph node cell suspensions, diluted 1:5 to 1:20 depending on cell density and containing 50’ to 
100’ cells, were loaded into the funnel of the cytospin glass container. In the second and third 
experiments, 200 μl lymph node cell suspensions diluted 1:30 for vehicle side and 1:60 for MC903 
side, were loaded into the funnel of the cytospin glass container. The container had a microscope 
slide and a punched filter paper mounted to it, with the funnel pointing towards the punched hole in 
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the filter paper on the glass slide. Glass containers were spun in a cytospin centrifuge for 5 minutes 
at 700 RPM, causing the fluid to be absorbed in the filter paper and the cells to attach on the 
microscope slide.  
All slides were subsequently stained with May-Grünwald-Giemsa solution. Thereafter, manual cell 
counts were performed on the whole surface containing cells, using a light microscope (Nikon 
Eclipse E200) at 400x magnification. In the results, lymph nodes were divided into groups by 
genotype (WT and 
+/-
 or 
-/-
), and by treatment (MC903 or vehicle).   
Cell counts in ear histological slides 
Inflammatory cell counts in ears were made using light microscopy (Nikon Eclipse E200) at 400x 
magnification of the histological slides. Numbers of cells were manually counted in five to twelve 
fields in each slide; results presented as individual means in genotype groups. All slides were 
blinded from individual markings during cell counting. Neutrophils were counted in slides stained 
with H&E and MCs were counted in slides stained with TB.  
Methods to analyze inflammatory mediators 
Enzyme-linked immunosorbent assays 
Enzyme-linked immunosorbent assay (ELISA) is a quantitative biochemical analyzing method, 
using antibodies linked to enzymes to detect and sometimes quantify specific substances in liquids. 
In this study, quantitative analysis of TSLP and IL-33 were performed.  
Thymic stromal lymphopoietin 
As one of the inflammatory parameters in this study, TSLP was chosen because of its connection 
with human and canine AD, described earlier. To analyze quantities of TSLP in serum and ear 
tissue, a commercial ELISA kit was used. For preparation of protein suspension used in the ELISA, 
the other halves of the mouse ears were deep frozen with liquid nitrogen and crushed into a fine 
powder. The powder was solved in 500 μl PBS with 1 % Triton-X; divided into two eppendorf 
tubes in which one of them, proteinase inhibitor (PI) was added to prevent enzymatic digestion 
(Complete, Mini PI cocktail Roche). All tubes were held on ice for 2 hours; centrifuged for 10 
minutes at 13’ RPM, thereafter both supernatants and pellet were frozen in -20˚C.  
Ear suspension supernatants in duplicates and diluted 1:20 were used for measuring local TSLP-
levels using mouse TSLP ELISA Ready-SET-Go! (eBioscience’s), according to instructions and 
with materials that followed the kit. Ear suspensions from five MC903-treated Wsh
+/-
, six Wsh
-/-
 
mice and five non-treated controls in both genotypes were analyzed, as well as 14 WT/mMCP-4
+/-
 
mice and six mMCP-4
-/-
 mice. The plates were read in a wavelength of 450 nm (A450) to produce 
optical density (OD) values, subsequently converted into concentrations using a standard curve. 
With the same kit, TSLP-levels were also analyzed in serum (diluted 1:7) obtained at day 2, 6 and at 
the end of trial. 
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Interleukin 33  
The concentration of the cytokine IL-33 was analyzed in ear suspensions because of its previously 
described association with AD as well as its potential as an in vivo substrate for chymase (Waern et 
al. 2013; Roy et al., 2013). Ear suspension supernatants in duplicates, diluted 1:20, from ten 
WT/mMCP-4
+/-
 mice and ten mMCP-4
-/- 
KO mice were analyzed using a DuoSet mouse IL-33 
ELISA Development kit (R&D Systems). Manufacturer’s protocol was followed, using supplied 
materials following the kit.   
Cytokine array 
A commercial kit, Mouse Cytokine Array Panel A (R&D Systems, Inc.), containing duplicate spots 
of capture antibodies directed against 40 different inflammatory cytokines and chemokines, was use 
to detect the mediators that are locally present after induction of AD with MC903. 
Ear suspensions from twelve chymase competent or - deficient mice were chosen, due to their high 
TSLP concentration as a marker of inflammation. Four mice had WT genotype, four mice mMCP-
4
+/- 
heterozygous genotype and four mice were of mMCP-4 KO genotype. Ear suspensions with PI, 
50 μl from each mouse in one genotype, were pooled into three samples with 200 μl that were used 
on each membrane. These samples were analyzed using Array procedure was done according to 
instructions appurtenant in the kit, using the kit-specific buffers and reagents. The detection of 
bound cytokines was mediated with paired antibodies. The secondary antibody was biotin labeled 
and thereafter streptavidin/dye was added. The signal was read in the Odyssey system (Li-Cor). 
Results were calculated as mean pixel density of the two spots, representing one cytokine or 
chemokine in the two genotypes. Since negative background values were removed in calculations, 
all cytokines with a visible bar in the figure were also present in the ear.   
Enzymatic assays 
Enzymatic assays are used for investigation of a specific enzymes’ activity on a substrate, 
measuring either the consumption of substrate or the amount of products generated during a 
specified period of time. In this study, the activity of the neutrophil enzyme elastase and the MC 
enzyme tryptase were measured in terms of changes in OD-values per hour, measured in a 
spectrophotometer. A cleavage assay was also performed to investigate whether the MC proteases 
tryptase and chymase are able to use TSLP as a substrate; samples were run in a gel to visualize 
cleavage products. 
Tryptase activity  
The activity of the MC protease tryptase was measured in duplicate ear suspension samples from 20 
WT/mMCP-4
+/-
 and 19 mMCP-4
-/- 
mice, using a chromogenic substrate (S-2288). Per well, 10 µl of 
ear suspension supernatant was mixed with 90 µl H2O in a 96-well plate which was read at 405 nm. 
Thereafter, 20 µl of the 1.8 mM enzyme substrate (S-2288) was added, and the plate was read every 
15 minutes until 2 hours, after which one final over night reading was done. Results were calculated 
as differences in OD-values per hour (A405).  
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Elastase activity  
To measure the local activity of the neutrophil enzyme elastase in ears, as a second parameter of 
neutrophil activity complementing the neutrophil counts, ear suspension supernatants from 25 
MC903-treated ears (whereof eleven KO mice) and twelve vehicle-treated mice (whereof four KO 
mice) were analyzed. 20 µl duplicate samples from each ear suspension were incubated in a 96-well 
plate at room temperature, together with 20 µl of enzyme substrate (Suc-Ala-Ala-Pro-Val-pNA) in 
a final concentration of 1 mM. To control the salt concentration, a balanced buffer containing 150 
mM NaCl 0,05 %, 100 mM TrisHCl, 0,1 % BSA and Tween-20 (pH 8,5) was added to a final 
volume of 200 µl per well. Duplicates with only buffer, and buffer with substrate, were used as 
blanks. OD values (A405) were determined every 15 minutes for 2 hours. One last reading was 
performed after incubation over night. Elastase activity was calculated as the difference in OD-
values per hour. 
TSLP cleavage by chymase and tryptase 
Three samples were prepared in eppendorf tubes, to study if TSLP is cleaved by the MC proteases 
tryptase and/or chymase: 
 0.5 µl TSLP (1 µg/µl) in 4.5 µl PBS (negative control) 
 0.5 µl TSLP (1 µg/µl) and 0.25 µl human (H) chymase in 4.25 µl PBS 
 0.5 µl TSLP (1 µg/µl) and 0.25 µl H-tryptase in 4.25 µl PBS 
Tubes were subsequently incubated in 37˚C for 40 minutes. To half of the samples, 5 µl 2x Sample 
buffer with 1 % 1 M dithiothreitol (DTT) was added. The sample buffer contains mainly sodium 
dodecyl sulfate (SDS), glycerol and bromophenol blue. SDS makes proteins negatively charged 
proportionally to their length, thus enabling separation of the proteins in gel electrophoresis.  
Glycerol gives the sample buffer higher density than the surrounding running buffer of the protein 
gel, enabling easy loading into the gel pockets. DTT breaks disulphide bonds. Thereafter, samples 
were boiled at 95˚ C for 6 minutes, quickly centrifuged and loaded onto a SDS-PAGE 
(polyacrylamide gel electrophoresis) 4 – 20 % gradient gel for separation of sample proteins. Gel 
was run at 200 V for 20 minutes, and visualization done through silver staining. 
The other half of the samples were sent to SciLifeLab for proteomic analyzes, using mass 
spectrometry to determinate possible cleavage sites for chymase and tryptase in TSLP.  
In vitro stimulation of peritoneal derived mast cells 
Peritoneal cell mast cells (PCMCs) were derived as described by Malbec et al. in 2007. Two WT 
mice were sacrificed using CO2 and peritoneal lavage with 4 ml PBS was performed to collect cells. 
These were subsequently cultured in media containing stem cell factor, with half of the media 
replaced once every third day. After three weeks, the PCMCs were transferred into duplicate wells 
containing media with either MC903 (1, 5 or 10 nmol) diluted in EtOH or only EtOH (5, 25 or 50 
µl) with 1x10
6
 PCMCs per ml as a concentration. Incubation with calcium ionophore was used as a 
positive control. After incubation for 1 hour or overnight, the cell suspension was cytospun onto 
glass slides and stained with May-Grünwald-Giemsa’s solution. Activation of MCs was calculated 
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and presented as percentage degranulated MCs of total cell number per field at 400x magnification, 
(Nikon Eclipse E200). 
Statistical analysis 
Statistical analyses were performed with Prism4 (GraphPad Software) using the Mann-Whitney test 
to compare rank values between different genotypes. This test was chosen because the parameters 
analyzed in the present biological systems do not follow normal distribution. The result of tryptase 
activity was analyzed according to the Unpaired T-test with Welsh correction because of the 
substantial individual variation. P-values <0.05 were considered significant. In the figures, P-values 
<0.001 were shown as ***, P <0.01 as **, and P <0.05 as *.  
18 
 
RESULTS 
The results of this study are presented in three separate parts: first, a pilot study was performed on 
W
sh
 mice, followed by a similar study using MCC deficient and - competent mice. A separate 
cleavage study that did not involve any experimental animals was also performed.  
Results in Wsh-mice 
MC903 induce visible AD-like skin changes, most apparent in MC deficient mice 
Treatment with MC903 created redness on the treated ear after 3 – 7 days. These changes developed 
into clearly visible thickening and dryness of the skin (see Figure 2). The lesions correspond well to 
those seen in canine and human patients with AD. After 13 days of treatment, all MC903-treated 
ears had at least a clinical score of 1, which corresponds to a mild redness and swelling. In vehicle-
treated ears, no visible changes were seen (clinical scoring = 0), which proves that it was MC903 
that caused these changes and not the ethanol-treatment.  
 
 
 
 
 
Figure 2. MC903-treated ear from a Wsh
-/-
 mice at day 0 and 13. 
Statistical analysis showed that the scores were not only significantly higher in MC903-treated ears 
compared to vehicle-treated ears, but a significantly higher score was also recorded for the W
sh-/-
genotype lacking MCs, compared to MC903-treated MC-competent mice (see Figure 3 below). This 
result indicates a protective role of MCs in the clinical appearance of MC903-induced dermatitis.  
 
 
 
 
 
Figure 3. Scoring of MC903- and vehicle-treated ears in W
sh
 mice. 
Day 0 
Day 13 
Day 
Day 0 
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MC903-treated ears increase in thickness, most apparent in MC deficient mice 
Ear thickness measured with an engineer’s micrometer was increased in all MC903-treated ears. 
The first week, only a minor increase in ear thickness was seen, which developed during the last 
days of the trial into a considerable thickening. The highest increase in one MC903-treated ear from 
day 0 to day 13 was 0.57 mm (measured in a W
sh-/-
 mice) and the lowest increase was 0.11 mm 
(measured in two W
sh+/-
 mice). Compared to vehicle-treated mice, where the highest increase was 
0.02 mm, did MC903 induce a significantly higher ear thickness (Figure 4). This proves that 
MC903-treatement induce thickening of the skin, a symptom that is also seen in atopic dermatitis. 
Statistical analysis between the two MC903-treated genotypes showed that ear thickness in MC 
deficient W
sh-/-
 mice was significantly higher compared to MC competent W
sh+/-
 mice (Figure 4), 
thus indicating a role of the MCs in limiting the ear thickening induced by MC903.   
 
 
 
  
 
 
 
 
 
Figure 4. Ear thickness in MC903-, vehicle- and non-treated ears in W
sh
 mice. 
Day 
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Ear sections on histology slides stained in H&E (representative photographs seen in Figure 5 
below), showed that the MC903-treated ears were substantially more thickened compared to the 
vehicle-treated ears, a result that corresponds well to the ear measurements done in vivo. MC903-
treated ears from W
sh-/-
 mice did also appear generally thicker than ears from W
sh+/-
 mice, as seen 
macroscopically. The observation that the epidermis was thicker in ears from MC-deficient than in 
ears from MC-competent mice implicates that MCs might have a specific role in the epidermal 
thickening typically seen in lesional skin from humans and dogs suffering from AD. Histology 
slides stained in TB (Figure 5) show an almost complete depletion of MCs in W
sh-/-
 mice and 
several degranulated MCs in W
sh+/-
 mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Histologic sections from MC903- and vehicle-treated ears in W
sh
 mice, H&E stained in 200x and 
TB stained in 400x (arrows pointing to mast cells). 
Wsh-/- Wsh+/- 
vehicle (H&E) 
MC903 (H&E) 
MC903 (TB) 
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More neutrophils in MC903-treated ears than in vehicle-treated ears in MC competent mice 
Manual cell counts on histological slides showed a higher infiltration of neutrophils in MC903-
treated ears compared to vehicle-treated ears. Statistical analysis showed a significant difference 
between MC903- and vehicle-treated W
sh+/-
 mice (Figure 6). In W
sh-/-
 mice, the difference between 
MC903- and vehicle-treated was non-significant. This could indicate that MCs contribute to the 
migration of neutrophils into the MC903-treated ear tissue. Inconclusively, no significant difference 
was seen between the two genotypes. This might be because of the high variability between 
individual mice in neutrophil migration and that some individuals reacted to vehicle-treatment with 
neutrophil migration. With one outlier removed, a vehicle-treated W
sh-/-
 mice, the difference 
between MC903- and vehicle-treated W
sh-/- 
mice is significant (p = *). 
   
 
 
 
 
 
 
 
 
 
Figure 6. Neutrophil numbers in MC903- and vehicle-treated ears in W
sh
 mice to the left, H&E stained ear 
from MC903-treated W
sh-/-
 mouse to the right (arrows pointing to neutrophils). 
MC903 induce higher TSLP concentration in MC competent mice than in MC deficient mice 
The ELISA kit for TSLP showed that MC903 induced increased concentrations of the AD-
associated cytokine TSLP, in both serum and ear suspensions. Locally in the ears, MC903-treatment 
induced a 15 to 50-fold increase in TSLP compared to vehicle-treated ears, a statistically significant 
increase in both W
sh+/-
 and W
sh-/- 
mice.  Not only was there statistically significance between 
MC903-treated and vehicle-treated ears, but the increase in TSLP concentration was also 
significantly higher in MC903-treated W
sh+/-
 compared to MC903-treated W
sh-/- 
mice. Data is shown 
in Figure 7.  
Wsh-/- 
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At day 6, serum concentrations of TSLP were very low; no significant difference was seen between 
the two genotypes or compared to non-treated controls. At day 13, concentrations were two to four 
times higher than in the non-treated controls.
 
Statistical analysis showed that W
sh+/-
 mice had 
significantly higher amount of TSLP in their serum, compared to W
sh-/- 
mice (Figure 7). These 
findings suggest that MCs have an important part in boosting the TSLP-production in this AD-
model.  
 
 
 
 
 
Figure 7. TSLP in ear suspension and serum in W
sh
 mice. 
Higher amount of IL-33 is induced by MC903 in MC competent mice compared to MC 
deficient mice 
The results from the ELISA-kit for IL-33 show that MC903-treated ears from W
sh+/-
 mice contained 
significantly higher concentrations of IL-33 compared to MC903-treated ears from W
sh-/- 
mice (see 
Figure 8). This supports the hypothesis that MCs is important in driving the production of IL-33.   
 
 
 
 
 
 
 
Figure 8. IL-33 in ears from MC903-treated W
sh
 mice. 
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Results in WT, mMCP-4+/- and mMCP-4-/- mice 
To investigate the role of MCC in this AD-model, the same kind of study was performed on WT, 
mMCP-4
+/-
 and mMCP-4
-/- 
mice. Results from WT and mMCP-4
+/-
 mice were presented together as 
one group since this did not affect the outcome of any of the statistical analysis performed. 
Genotyping results shows mendelian randomization 
Among the 41 mice genotyped, eleven mice were of WT genotype, eleven of KO genotype 
(mMCP-4
-/-
) and the rest, 19 mice, of mMCP-4
+/-
 genotype (Table 2). This result is close to a 
perfect mendelian randomization, which confirmed that the breeding is functioning as expected.  
MC903 induce visible AD-like skin changes, in WT, mMCP-4+/- and mMCP-4-/- mice 
Ear-treatment of MC903 led to similar changes in WT, mMCP-4
+/-
 and mMCP-4
-/-
 mice as in the 
W
sh
 mice: redness, flaky skin and ear thickening, seen in Figure 9 below.  
 
  
 
 
Figure 9. MC903-treated ears from one mMCP-4 mice at day 0 and 13. 
As in the group of W
sh
 mice, all MC903-treated ears had a clinical score of at least 1 at the end of 
trial whilst no visible changes were seen in vehicle-treated ears. Statistically, no significant 
differences were seen between the different genotypes, WT, mMCP-4
+/-
 and mMCP-4
-/- 
(Figure 10). 
This shows that MC903 induce an AD-like phenotype without a critical involvement of the MC 
protease chymase. 
 
 
 
 
 
 
 
 
Figure 10. Scoring of MC903-, vehicle- and non-treated ears in WT/mMCP-4
+/-
 and mMCP-4
-/-
 mice. 
MC903 induce an increase in ear thickness in WT, mMCP-4+/- and mMCP-4-/- mice 
Day 0 Day 13 
Day 
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Ear thickness was significantly increased by MC903-treatment in all genotypes, compared to both 
vehicle- and non-treatment. As seen in the W
sh
 mice, the increase in ear thickness in the WT, 
mMCP-4
+/-
 and mMCP-4
-/-
 mice was mild until about one week into the trial, from where the ear 
thickness increased in a higher pace. No difference was seen between the two genotypes (Figure 
11). This shows that the ear thickness induced by MC903 is apparent but is not influenced by MCC. 
 
 
 
 
 
 
Figure 11. Ear thickness in MC903-, vehicle- and non-treated ears in WT/mMCP-4
+/-
 and mMCP-4
-/-
 mice. 
In ear sections on histology slides stained in H&E from mMCP-4 mice, seen in Figure 12 below, 
MC903-treated ears were substantially more thickened compared to the vehicle-treated ears, similar 
to the result seen in W
sh
 mice (Figure 5) and well corresponding to the ear measurements done in 
vivo. No apparent difference was seen between the genotypes. 
 
 
 
 
 
 
 
 
 
 
Figure 12. Histologic sections in 200x from MC903- and vehicle-treated ears in WT and mMCP-4
-/-
 mice. 
vehicle 
MC903 
WT mMCP-4
-/- 
Day 
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Topical application of MC903 induces MC migration to auricular draining lymph nodes 
At the end of trial, the auricular lymph nodes were collected. Visually, the left sided lymph nodes 
(draining the MC903-treated ears) were clearly enlarged compared to the lymph nodes on the right 
side (draining the vehicle-treated ears). Manual cell counts in cytospun suspension from the 
auricular lymph nodes, showed no significant difference between the genotypes, whether MC903-
treated or vehicle-treated (Figure 13), which indicates that the absence of chymase do not affect the 
migration of MCs in this model. However, in all genotypes (WT, mMCP-4
+/-
 and mMCP-4
-/-
) did 
MC903-treatment significantly increase the number of MCs in the ear draining lymph nodes, 
compared with vehicle-treatment (Figure 13) thus proving that this AD-model involves MCs.  
 
 
 
 
 
 
 
Figure 13. MC count in draining lymph node of MC903- and vehicle-treated ears in WT/mMCP-4
+/-
 and 
mMCP-4
-/- 
mice. 
MC903-treated ears have higher numbers of MCs than vehicle-treated ears 
Significantly higher numbers of MCs was seen in MC903-treated ears compared to vehicle-treated 
ears (Figure 14), which shows that the inflammation started by MC903 involves MCs. The 
percentage of degranulated and thus activated MCs was also higher in MC903-treated ears (Figure 
14), thus proving an activity of the MCs due to MC903-treatment. No significant difference was 
seen between the WT/mMCP-4
+/-
 and mMCP-4
-/-
 mice which further add to the conclusion that 
MCC do not have an indispensible role in this MC903-induced AD-model.   
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Figure 14. MC count and degranulation in MC903- and vehicle-treated ears in WT/mMCP-4
+/-
 and mMCP-
4
-/-
 mice. 
Tryptase activity is higher in MC903-treated ears than in vehicle-treated ears  
 A markedly high individual variance was observed in the activity of the MC protease tryptase; 
therefore, statistical analyze was performed using Unpaired T-test with Welch correction. This 
showed a significantly higher activity in both genotypes treated with MC903 compared to vehicle-
treatment (Figure 15). This confirms MC activity in this AD-model and suggests that tryptase might 
have an important role in the inflammation. No significant difference was seen between the 
genotypes, an expected result as the lack of chymase should not affect the tryptase activity.  
 
 
 
 
 
 
 
 
 
Figure 15. Tryptase activity in MC903- and vehicle-treated ears in WT/mMCP-4
+/-
 and mMCP-4
-/-
 mice. 
More neutrophils and higher elastase activity in MC903-treated ears compared to vehicle-
treated ears in MCC competent mice 
Manual cell counts in ears sections stained with H&E, showed significantly higher numbers of 
neutrophils in MC903-treated WT, mMCP-4
+/-
 and mMCP-4
-/- 
mice compared to vehicle-treated 
ears from the corresponding genotype group (Figure 16). No significant difference was seen 
between the genotypes, thus proving that MC903 induce neutrophil skin migration but at the same 
time minimizing the likeliness of MCC being involved in the neutrophil migration.  
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The activity of the neutrophil enzyme elastase was significantly higher in MC903-treated WT and 
mMCP-4
+/-
 ears compared to vehicle-treated ears from the same group (Figure 16), thus confirming 
that local neutrophil activity is increased as a response to MC903-treatment in MCC competent 
mice. Neutrophil activity was not significantly higher in MC903-treated mMCP-4
 
KO mice than in 
vehicle-treated mice of same genotype and no significant difference was seen between the two 
genotypes in neither MC903-treated nor vehicle-treated ears. There is however one outlier in the 
MC903-treated mMCP-4
-/-
 genotype group, with much higher elastase activity than the other 
individuals in the same group. If this value is excluded, the difference between the two MC903-
treated genotype groups is significant (*), thus giving a weak connection between MCC and 
neutrophil migration.
 
 
 
 
 
 
 
 
Figure 16. Neutrophil numbers and elastase activity in MC903- and vehicle-treated ears in WT/mMCP-4
+/-
 
and mMCP-4
-/-
 mice. 
MC903 induce increased TSLP concentration in ear suspension and serum 
In all of the genotypes analyzed (WT/mMCP-4
+/-
 and mMCP-4
-/-
 mice), MC903-treated ears 
contained significantly more TSLP compared to vehicle-treated ears (Figure 17), a result that adds 
to the proof of TSLP being an important cytokine in driving the MC903-induced inflammation, 
mimicking AD. No difference separated mMCP-4 KO mice from the other genotypes; no effect of 
chymase on the TSLP-levels could therefore be detected. 
Similar results were seen in serum. TSLP-levels were significantly higher in all MC903-treated 
mice on day 6 and 13, irrespectively of genotype, compared with serum-levels in non-treated mice 
(Figure 17). This result concludes that MC903 also induce systemically effects in the treated mice. 
On day 2, TSLP-levels were very low and mMCP-4
-/-
 mice did not have significantly higher levels 
than non-treated mice. The highest levels of TSLP were detected on day 6, resulting in significant 
differences in both genotype groups compared to corresponding values seen in day 2 and 13. No 
significant differences were seen between the genotype groups, further adding to the conclusion that 
chymase is not needed for the MC903-induced increase in TSLP. 
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Figure 17. TSLP in ear suspension and serum from WT/mMCP-4
+/-
 and mMCP-4
-/-
 mice. 
Higher amount of IL-33 is induced by MC903 in mice lacking chymase compared to WT mice 
Significantly higher amounts of IL-33 were observed in the ears of mMCP-4
-/-
 mice than in ears 
from WT and mMCP-4
+/-
 mice (Figure 19), but with a lower concentration in MC-deficient mice., 
indicating that MCs either produce significant amount of IL-33 or promote the production of IL-33 
in AD (Figure 8), the MC protease chymase seems to have a role in lowering the concentration of 
IL-33, probably through cleavage of the cytokine. 
 
 
 
 
 
 
 
 
 
Figure 18. IL-33 in MC903-treated ears from in WT/mMCP-4
+/-
 and mMCP-4
-/-
 mice. 
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MC903 induce local production of a wide range of inflammatory cytokines 
A qualitative cytokine array was performed, investigating which cytokines that were produced in 
ears following MC903-treatment. The result shows a massive production of inflammatory 
mediators, seen in Figure 19. Previously mentioned cytokines associated with Th-2 immune 
responses that were present in this AD-model are IL-4, IL-5, IL-6 and TNF-α, thus proving that the 
inflammation includes Th-2 cytokines; IL-13 is also present but not as obvious as the others. IL-12, 
an important Th-1 cytokine, is the only cytokine in this array that shows no activity, further 
implicating a predominant Th-2 milieu. One Th-1 associated cytokine, IFN-ᵧ, is present, however 
with an indistinct result (low mean pixel density). The other cytokines present in the array will not 
be discussed in this study, because of the limited duration of the project. The information will 
instead be used in following research.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19.Cytokines and chemokines in MC903-treated ears in WT/mMCP-4
+/-
 and mMCP-4
-/-
 mice. 
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Results in cell culture 
In vitro stimulation of peritoneal derived mast cells 
MC903 cause degranulation of PCMCs in higher extent than vehicle 
PCMCs incubated with MC903 did degranulate in significantly higher percentages compared to 
cells incubated with ethanol (EtOH), which was used as a vehicle in the in vivo part of present study 
(Figure 20). An average of 28 % of the PCMCs were degranulated after one hour of incubation and 
a mean of 50 % degranulated PCMCs were seen after overnight incubation, using the same amount 
of MC903 as in the in vivo study.  
Higher amounts of MC903 (5 and 10 nmol) caused close to 100 % of the PCMCs to degranulate, 
but were also toxic as many of the cells died. PCMCs incubated with 95 % EtOH were degranulated 
in an average of 15 – 20 % regardless of amount (5, 25 or 50 μl) and time (1 hour or overnight), 
with one exception; PCMCs incubated with 50 µl EtOH overnight degranulated in a percentage 
close to 50, but this was still significantly lower than PCMCs incubated with high amount of 
MC903 overnight.   
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Percentage of degranulated PCMCs incubated with MC903 and ethanol. 
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Results of cleavage study 
TSLP cleavage by chymase and tryptase 
TSLP is cleaved to higher extent by tryptase than by chymase 
The cleavage study, where TSLP was incubated for 40 minutes together with two different human 
MC proteases, showed that TSLP was cleaved at a higher extent by tryptase than by chymase. In 
Figure 21, cleavage is visualized by silver staining where 1 = molecular-weight size marker, 2 = 
TSLP + chymase, 3: TSLP + tryptase and 4 = negative control (only TSLP). As shown in Figure 21, 
the protein band in 2 is somewhat brighter than in 4, corresponding to a minor cleavage of TSLP by 
chymase. Number 3 shows a total cleavage of TSLP by tryptase. Thus, tryptase does degrade TSLP 
rapidly and completely, whilst chymase during a shorter period of time does minimal degradation of 
TSLP.  
 
 
 
 
 
 
 
Figure 21. Photography of a gel ran in the TSLP cleavage study with chymase and tryptase. 
These results are in agreement with those received from SciLifeLab performing proteomic analysis, 
showing that the MC protease tryptase had several potential target sites in TSLP, whilst chymase 
only had one (data not shown).  
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DISCUSSION 
The aim of this study was to establish an AD mouse model, new to the laboratory. The use of a low-
calcemic vitamin D3 analog (MC903) on KO mice, deficient in MCs (W
sh-/-
, Grimbaldeston et al., 
2005) and MCC (mMCP-4
-/-
, Tchougounova et al., 2003), to create an AD-like phenotype gave the 
opportunity to investigate the role of MCs and MC mediators in the clinical and biochemical 
progression. Analyzes performed during this study showed that MC903 induced a number of 
inflammatory changes in both W
sh
 and mMCP-4 (WT, mMCP-4
+/-
 and mMCP-4
-/-
) mice, similar to 
those seen in human and canine AD-patients thus confirming the use of MC903 to create a 
functioning mouse model.  
There are some rather important aspects that separate this model from other AD-models. Tanaka et 
al. (2012) reviewed different AD animal models, induced either by an intravenous injection of IgE 
anti-haptens prior to antigen challenge, or by tape stripping prior to repeated allergen challenges. 
These methods have a more complicated performance, are more time consuming and do cause a 
substantially higher level of stress in the treated mice. Inducing dermatitis with one drop of MC903 
on each side of the ear is a simple procedure that the mice get used to fairly quickly. No obvious 
protests are seen until only the last couple of days, when more apparent changes are visible. 
Therefore, the MC903-induced mouse model for AD is a non-expensive and simple method with 
minimal negative effects on the mice.   
In most of the results produced in this study, MC903 was shown to induce changes mimicking a 
naturally occurring AD. Macroscopically, redness, dermal thickening and flaky skin was seen, 
which corresponds well to the early changes seen in humans and dogs suffering from AD (Marsella 
& Girolomoni, 2009). If pruritus, the most prominent symptom of human and canine AD, is evoked 
by MC903, was however not clarified in this study, since available methods used to measure 
scratching are too advanced and expensive for this kind of short term project. For example, Tanaka 
et al. (2012) describes a method with a high-speed camera connected to a computer program, but 
other methods are far more invasive, such as surgically insertion of a magnet into the hind paws of 
the mice done by Terakawa et al. in 2008.  During the course of the MC903-treatment in this 
project, more scratching behavior was seen in the last period before the endpoint of the study. 
Without any measurement of this parameter, no conclusion concerning itch could be done. Since the 
study was ended before any mice showed severe changes, none of the later changes in AD, such as 
hyperpigmentation was seen. Surprisingly, mice lacking MCs reacted significantly higher to 
MC903-treatment in both scoring and ear thickening, thus implicating a protective role of MCs 
against clinical development. MCC cannot be accounted for this function, since no significant 
clinical difference was seen between the WT, mMCP-4
+/-
 and mMCP-4
-/-
 genotypes. Knowing that 
MCs have the ability to limit inflammation, for example via the negative effects of IL-10 on the 
secretion of pro-inflammatory cytokines (Tsai et al., 2011), it would be interesting to further 
evaluate the levels of IL-10. To ensure that this limiting effect by MCs truly exists, at least two 
more separate experiments in W
sh
 mice would be necessary. Because of the short period of time, it 
was not possible to perform any more trials within this project, but continued studies on this subject 
are recommended.  
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Microscopically, epidermal thickening with inflammatory cell infiltration to a varying degree was 
seen in all MC903-treated ears of the present study (Wsh
+/-
, Wsh
-/-
, WT, mMCP-4
+/-
 and mMCP-4
-/-
), similar to the typical changes known to exist in naturally occurring AD (Olivry et al., 1997).  
Histological examination did not show a spongiotic type of dermatitis, typically seen in skin from 
AD patients. This might be due to the fact that AD in humans and dogs is associated with inherited 
immunological traits creating a microenvironment with Th-2 character and impairing the skin 
barrier, leading to widened intracellular spaces in the stratum corneum called spongiosis (Kamsteeg 
et al. 2011). Therefore, mice without these genetic immunological traits will not exhibit those 
specific alterations, even though an AD-like phenotype is seen.  
MC903-treatment did significantly increase the number of neutrophils in the ears of WT, mMCP-
4
+/-
, mMCP-4
-/-
 and W
sh+/-
 mice compared to vehicle-treated mice. In W
sh-/-
 mice, the increase was 
however not significant. This result could be interpreted as a role of MCs in the migration of 
inflammatory cells in this AD-model, but since no significant difference in neutrophil numbers 
could be seen between W
sh+/-
 and W
sh-/-
 mice, no definitive conclusion could be made. MCs are 
known to alter homeostasis and enhancing adhesion of neutrophils to endothelium which enables 
migration into the skin (Liu et al., 2011). Elastase was measured as an additional parameter of 
neutrophil activity. It showed a similar result with significantly higher activity in MC903-treated 
WT and mMCP-4
+/-
 mice compared to vehicle-treated ears, but no significance between treated and 
non-treated mMCP-4
-/-
 mice. With one outlier excluded in the mMCP-4
-/-
 genotype group, the 
difference between the MC903-treated WT/mMCP-4
+/-
 and mMCP-4
-/-
 mice was significant (*), 
thus supposing a connection between MCC and neutrophil migration.  MCC is known to use 
Angiotensin I as a substrate why chymase also is proposed as having a role in generating 
Angiotensin II (Pejler et al., 2007). This component of the Angiotensin system has been shown to 
stimulate neutrophil migration by for example Elferink et al. (1997), hence making a role of MCs 
and MCC in the neutrophil migration explainable. Since these results were not all clear, a higher 
number of individuals should be analyzed for a more conclusive result. 
MC numbers were significantly increased in lymph nodes draining MC903-treated ears, as was 
tryptase activity in all ears from WT, mMCP-4
+/-
 and mMCP-4
-/-
 mice, thus confirming that MC903 
activates MCs and cause migration of the cells into the lymph nodes. MCs may contribute to the 
promotion of a Th-2 dominated environment in the lymph nodes, through production of Th-2 
associated cytokines (Metcalfe et al., 1997). MCs might also present antigen to T-lymphocytes 
(although DCs are the most important APCs), which subsequently become Th cells of type 2 that 
are associated with humoral immunity and IgE production. The lack of chymase did not affect this 
studied parameter significantly, suggesting that MCC do not affect MC migration in this MC903-
induced AD model. However, the potential involvement of MCC in MC migration could be further 
evaluated in the MC903-induced AD model with increased or lowered doses of MC903 in future 
projects. 
Biochemical analyses also showed similar AD-like inflammatory changes due to MC903-treatment, 
for example the presence of Th-2 associated cytokines such as IL-4, IL-6 and TNF-α, as well as an 
increase of the AD-associated cytokines TSLP and IL-33. TSLP, a cytokine that functions as a 
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“master switch for allergic inflammation” according to Liu (2006), was shown to increase locally in 
the ears after repeated applications of MC903. In MC-competent mice, the increase was more than 
65 times the levels of vehicle-treated ears and in MC-deficient mice, TSLP increased less than 
twelve times. The results indicate a role of MCs in driving the increase of TSLP. Although MCs are 
able to produce TSLP by themselves (Okayama et al., 2009), it is more likely that a significant part 
of their contribution to the TSLP-increase occurs indirectly, through production of mediators that 
enhance TSLP-expression in other cells, since the MCs are clearly outnumbered in the skin by 
epithelial cells and keratinocytes. For example, MCs are according to Tsai et al. (2011) able to 
promote the production of TSLP from epithelial cells through the cytokines IL-4, IL-13 and TNF-α. 
Since the TSLP-levels were similar in mice lacking MCC compared to MCC-competent mice, this 
protease does not seem to affect TSLP expression in MC903-induced AD. 
The result of ELISA for IL-33 shows that MC903-treatment induces a local increase of the 
cytokine, with significantly higher levels in MC-competent mice. This is probably due to similar 
reasons as to why TSLP-levels are higher in mice with than without MCs, namely an indirect 
activation of IL-33 by epithelial cells through mediators produced by MCs. Since the numbers of 
MCs is comparatively low, it is less plausible that the loss of MC-produced cytokines would cause a 
significant difference. IL-33 was also increased in WT and mMCP-4
+/-
 mice after MC903-
treatment, although not significantly. These results are similar to those produced by Hueber et al. in 
2011, where MC-deficient mice (W
sh-/-
) had lower levels of IL-33. Interestingly, MCC-deficient 
mice had significantly higher levels of IL-33, which implies a limiting role of chymase, most likely 
due to cleavage of the cytokine. Recently, it was shown that IL-33 is in fact cleaved by chymase 
(Roy et al., 2013), thus confirming this hypothesis. Since the clinical parameters in the mice lacking 
mMCP-4 were not significantly different to mMCP-4 competent mice, the effect by chymase on IL-
33 levels does not seem to be of major importance in this MC903-induced AD-model. 
One question raised when using a KO mouse in research, is if there are other phenotypic changes 
caused by genetic alteration that could affect the clinical outcome. The mMCP-4
-/-
 mice have a 
specific mutation in the gene coding for the MC protease 4 that share functional similarities to 
human chymase and no other functional or morphological changes in the MCs have been seen 
(Tchougounova et al., 2003). In this study, no visible differences were seen between the mMCP-4 
competent mice compared to the mMCP-4 deficient mice. W
sh-/-
 mice carries an inversion mutation 
in the white spotting (W) locus, also called the c-kit gene, which affects melanocytes and creates a 
major deficiency in MCs. Grimbaldeston et al. (2005) showed that W
sh-/-
 mice have normal levels of 
B- and T-cells, granulocytes, macrophages and basophils in bone marrow; as well as splenic B-
cells, granulocytes, macrophages, DCs and natural killer cells. In later research, W
sh
 mice have been 
shown to carry some other hematopoietic alterations, such as higher numbers of neutrophil 
granulocytes and thrombocytes, accompanied by an enlargened spleen (Nigrovic et al., 2008), the 
later phenomenon clearly apparent in this study as well. Since no significant difference in 
neutrophil numbers was seen between vehicle-treated ears from W
sh+/-
 and ears from W
sh-/-
 mice, the 
generally higher levels of neutrophils in W
sh-/-
 mice does not seem to affect local neutrophil 
numbers and therefore should not affect the results seen in this study.    
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To strengthen the evidence that differences seen in experimental KO mouse studies is truly caused 
by the specific deficiency of cells/cell mediators, it is common to use a method in which the lacking 
component is reinserted. Changes between the genotypes should thereby no longer be detectable. 
This reconstitution is achieved either by injection of cultured MCs, for example from the bone 
marrow, or by transplantation of the whole bone marrow from WT mice (Grimbaldeston et al., 
2005). Although a reconstitution of MCs in the W
sh-/-
 mice would be of interest to make sure that 
the changes seen in this AD-model are in fact MC-dependent, it was not an option due to the time 
limit of this project. 
As always, it is important to recognize the weaknesses in these kinds of mouse models, since a 
mouse is neither a human nor a dog. The present differences between species make it difficult to 
extrapolate any conclusions directly to humans based on these results seen in mice, especially since 
there are tremendous amount of molecular biology that is still not fully understood. In spite of this, 
mouse models do contribute substantially to this essential area of research. As new discoveries in 
molecular biology are made, mice may serve as a potential source of relatively cheap in vivo models 
with short generation time and the possibility to study large litter sizes. Mice are small, thus 
acquiring considerable less space than dogs for example, easy to handle and have enough 
adaptability to thrive in a laboratory environment. More importantly, methods to alter their 
genotype and subsequently create mouse disease models are highly developed. Studies such as this 
one, inducing a disease-like phenotype in KO mice lacking specific cells or cell mediators due to 
genetic alteration, give a unique opportunity to thoroughly investigate the role of specific cells or 
mediators in a disease-model. New discoveries made in mice could subsequently be further 
investigated in humans, to conclude if similar connections are present. 
To complement all of the analyses performed in the mouse model, a small in vitro experiment was 
also performed. Since the PCMCs used in the study did only originate from two individual mice, the 
result could not be completely signified. In spite of this, the result do imply that MC903 is able do 
directly activate MCs, since significantly more MCs did degranulate when incubated with MC903 
in comparison to when incubated with ethanol. The fact that MC903 at higher doses were toxic to 
the MCs is not surprising, since mice treated with high doses of MC903 died in the previous study 
by Li et al. (2006).   
Since no marked involvement of MCC was seen in this model, a new focus on tryptase could 
contribute to further understanding the role of MCs in AD. The result from the cleavage study 
performed, confirmed that the cleavage of TSLP by chymase was not as pronounced as the cleavage 
by tryptase. Tryptase was also shown to have several potential cleavage sites in TSLP, compared to 
only one by chymase. These results suggest that tryptase might be more important than chymase in 
the development of AD, thus giving an opportunity for continuous studies using MC903 to induce 
AD in KO mice lacking tryptase. 
As a conclusion, it was shown that MC903 in a simple method induced an AD-like phenotype in 
both mouse strains used in this study, visible both macro- and microscopically. Without the impact 
of MCs, the ear thickness was highly increased, indicating a limiting role of MCs in the clinical 
development of the MC903-induced AD-like symptoms. This result needs further proof to be 
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conclusive, since only one trial with W
sh
 mice was performed. The other parameters were lowered 
without MCs, such as the cytokine levels of TSLP and IL-33 locally and TSLP systemically, 
creating a clear indication that the MC903-induced AD-model is MC-dependent. This result was 
expected since MCs have many important features in the immunopathogenesis of AD. A non-
proved sign of lowered neutrophil migration was also seen, a result that also would need further 
research. MCC did exhibit one clear function in this study, namely to limit the local levels of IL-33, 
most likely through cleavage, as well as one less apparent function in the migration of neutrophils 
into to skin. TSLP, which seems to be a very important cytokine in the MC903-induced AD-model, 
was shown to be relatively unaffected by MCC.  
As a continuation of this study, it would be interesting to shorten or lengthen the trial, to investigate 
whether MCs and MCC have different effect on the skin inflammation in earlier or later phases. 
Since the qualitative kind of cytokine array only answers the question if and not how much of the 
cytokine that is present, the next step was to perform specific analyzes on the cytokine of interest. 
Due to the short time limit of this project (three months), the results could not be followed with 
quantitative analysis. However, there will be continued research in this area, in where these results 
may be of importance.    
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CONCLUSIONS 
In all of the mice included in this study, whether WT, MC-deficient or -competent, having or 
lacking MCC, MC903-treatment was shown to induce macroscopically visible and measurable 
changes locally in the ears. In histological examination, the treated ears had a clearly thickened 
epidermis with prominent inflammatory cell infiltration, thereby consisting of e.g. MCs, neutrophils 
and lymphocytes. These changes correspond to those seen in human and canine cases of AD. The 
typical spongiotic changes with epidermal edema were however not seen. This may probably be due 
to it being an inherited, primary feature of AD-patients and therefore not present in the mice used in 
this experimental study. 
Biochemical analysis confirmed that MC903-treated ears contain AD-associated cytokines, both 
locally in the ears (TSLP, IL-33 measured by ELISA and IL-4, IL-13 measured by cytokine array) 
and systemically in serum (TSLP). These interleukines have also been shown to be produced by 
innate immune cells after TSLP-activation (Ziegler et al., 2012), which further strengthen the idea 
that MC903 induce an AD-like phenotype via TSLP. A Th-2 dominated cytokine milieu was 
observed in the MC903-treated ears with e.g. IL-4, IL-6 and TNF-α, similar to naturally occurring 
AD. On the contrary, the Th1 cytokine IL-12 was the only cytokine not detected. 
To summarize the vast number of results produced in this study, Table 3 shows the effect seen on 
the different genotypes following MC903-treatment, compared with the results from vehicle-
treatment. In the left columns under the different genotypes, the number of arrows quantifies the 
increase of the different inflammatory parameters. One arrow corresponds to a low increase (↑), two 
means a moderate increase (↑↑) and three arrows correspond to a massive increase (↑↑↑), compared 
to vehicle-treatment. Statistical significance is shown inside parenthesis (P <0.001 = ***, P <0.01 = 
** and P <0.05 = *). The right columns under each genotype show statistical significance of the 
MC903-induced increase, compared to MC903-treated mice of opposite genotype.    
Table 3. Summary of results following MC903-treatment, compared to vehicle-treatment 
 W
sh+/-
 W
sh-/-
 WT & mMCP-4
+/-
 mMCP-4
-/-
 
 Treated vs. 
Control 
P-
value 
Treated vs. 
Control 
P-
value 
Treated vs. 
Control 
P-
value 
Treated vs. 
Control 
P-
value 
Clinical scoring ↑  ↑↑ ** ↑↑  ↑  
Ear thickness ↑ (***)  ↑↑ (***) * ↑↑ (***)  ↑↑ (**)  
MC numbers in LN n.a.  n.a.  ↑↑ (*)  ↑↑ (**)  
MC numbers in ears n.a.  n.a.  ↑ (**)  ↑ (**)  
Tryptase activity n.a.  n.a.  ↑↑ (***)  ↑↑ (*)  
Neutrophil numbers in ears ↑ (*)  ↑  ↑↑ (***)  ↑↑ (**)  
Elastase activity n.a.  n.a.  ↑ (*)  -  
TSLP in serum ↑↑ (*) 
*
* ↑↑ (*)  ↑↑  ↑↑  
TSLP in ears  ↑↑↑ (**) * ↑↑ (**)  ↑↑↑ (***)  ↑↑ (**)  
IL-33 in ears ↑↑↑ * ↑↑  ↑  ↑↑ * 
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The results in Table 3 show that MC903-treatment induced significant increases in various means 
compared to vehicle-treatment, but that some of the significant changes were only seen in one of the 
genotypes, indicating some kind of effect on the AD-like development by MCs and MCC. For 
example, higher neutrophil counts accompanied by higher elastase activity were seen in mice 
having MCs and MCC but not in the KO mice, thus implying a contribution of both MCs and MCC 
to neutrophil migration. On the contrary, no significant differences were seen between the MC903-
treated genotypes, making it somewhat difficult to draw a clear conclusion. 
The involvement of MCs in this AD-model is hence only proved in three of the analyzed 
parameters: clinical development, TSLP-levels and IL-33 levels. MCC does only seem to affect the 
IL-33 levels, although some signs of involvement by MCC in the elastase activity are also seen. As 
a conclusion, MC-deficient mice have a higher clinical response to MC903, thus indicating a 
protective role of MCs in limiting the skin inflammation, but at the same time do they have lower 
levels of the cytokines TSLP and IL-33; both with previously mentioned connections to AD. 
In the small in vitro study performed, incubation with MC903 was shown to induce activation 
through degranulation of PBMCs to a higher extent than incubation with ethanol, thus proving that 
MC903 also has a direct effect on MCs. This is likely to be one important cause of the significant 
changes in inflammatory response seen in MC-deficient mice compared to MC-competent mice in 
vivo.  
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